doi: 10.2337/dc05-1365
Offering both efficacy and tolerability, clinical trials as of early 2023 indicate that patients may experience significant weight reduction that often exceeds results from traditional approaches, situating semaglutide as a promising tool in the weight management arsenal
Subcutaneous injection delivers ipamorelin into the hypodermis, where it diffuses into capillaries and enters systemic circulation without encountering digestive enzymes
For an intramuscular shot that goes deep into the muscle (like in the arm or buttocks), a longer, slightly thicker needle is needed to reach the target
From a safety perspective, adverse effects such as pancreatitis and gallbladder disease can occur at any dose, and the risk profile at microdoses is undefined
In the SURMOUNT-1 Phase 3 trial (N=2,539), Tirzepatide at 15mg produced 22.5% mean weight reduction over 72 weeks compared to 2.4% for placebo